Patent Application
20170305943
This application claims priority to Australian Provisional Patent Application No. 2014901885, filed May 21, 2014, and Australian Provisional Patent Application No. 2014901912, filed May 22, 2014, the entirety of which is incorporated herein by reference.
The present invention relates to compounds for the treatment of bacterial infections. More particularly, the invention relates to compounds that demonstrate antibacterial activity, their use in methods for the treatment of bacterial infections, a new class of compounds per se, pharmaceutical compositions comprising them and processes for their manufacture.
Bacterial infections are responsible for many human conditions and illnesses and in severe cases can be life-threatening. Many classes of antibacterials have been developed since the discovery of penicillin including the cephalosporins, fluoroquinolines and quinolines, monobactams, rifamycins, aminoglycosides, glycopeptides, macrolides and so on. However, the emergence of bacterial resistance to known classes of antibacterials is of increasing concern as is the low output of novel antibacterial drug classes over the past few decades. Thus there is international recognition of the long-felt and ongoing need for new antibacterials, particularly to address the issue of emerging resistance (Silver, L. L., Challenges of Antibacterial Discovery, Clinical Microbiology Reviews, January 2011, Vol. 24, No. 1, p71-109).
Clostridium difficile (CD) is a Gram-positive anaerobic bacterial pathogen. Clostridium difficile infections (CDIs) are considered to be one of the most important causes of health care-associated infections (HAIs). In early 2001, there was an observed increase in the severity of CDI and the number of patients diagnosed in the US with intestinal infections resulting from CD. In 2002 severe and recurrent outbreaks of CD occurred in Canada. The cause of these outbreaks has since been associated with the now highly prevalent and virulent strain NAP1/BI/027 and this epidemic strain has spread to England and parts of continental Europe.
Studies have demonstrated that 50% or more of hospital patients infected with CD are symptomless carriers. However, for those patients who have symptoms, these symptoms include mild to moderate diarrhoea, nosocominal antibiotic associated diarrhoea, community acquired diarrhoea, fulminant and even fatal pseudomembranous colitis. Complications of severe CD colitis include dehydration, electrolyte disturbances, hypoalbuminemia, toxic megacolon, bowel perforation, hypotension, renal failure, systemic inflammatory response syndrome, sepsis and death (Cohen, S. H., et. al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA), Infection Control and Hospital Epidemiology May 2010 Vol. 31. No. 5, p 431-455).
CDI occur in the gastrointestinal tract. The particular challenges associated with treating CDI include the disruption or suppression of normal bowel flora by the administration of antibacterials which enables the CDI to flourish. Accordingly, CDIs infections are often associated with antibacterial use and increased susceptibility is commonly observed with longer exposure to antibacterial therapy and exposure to multiple antibacterials. Other risk factors for CDIs include advanced age, duration of hospitalisation, cancer therapy, immunocompromised patients such as those with human immunodeficiency virus (HIV) and patients undergoing abdominal or gastrointestinal surgery or manipulation of the gastrointestinal tract such as tube feeding. Also of concern is the recent observance of CDIs among previously low risk populations such as healthy peripartum women.
Although current antibacterial therapy for CDI infections comprises administration of metronidazole and/or vancomycin, these compounds disrupt intestinal flora leaving patients susceptible to recurrences of bacterial infections. Furthermore, the reduced effectiveness of metronidazole has been observed and it is not recommended beyond the first recurrence or for long-term chronic therapy due to the potential for cumulative neurotoxicity.
The present inventors have discovered a class of compounds with demonstrated activity against CD. The class of compounds includes compounds previously described in WO2007/107758, WO2009/037485, WO2009/040507 and WO2012/142671 (each of which is incorporated by reference) as well as novel compounds per se.
Accordingly one embodiment provides a method for treating a Clostridium difficile infection comprising administration of a compound of Formula (I″):
to a patient with said infection or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein:
A ring is optionally substituted with one or more substituents;
G is
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1-6alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
Z is CH or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
X is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles; and
R is optionally substituted and is selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
Q is selected from O, CH2 or NR7 where R7 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
J is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, optionally interrupted by an ether linkage; and
A2 is optionally substituted and is selected from C6-10aryl and 5-10-membered heterocycles.
One embodiment provides a method for treating a Clostridium difficile infection comprising administration of a compound of Formula (I) or Formula (II):
to a patient with said infection or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein:
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1 alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
Z is CH or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
X is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles; and
R is optionally substituted and is selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
R5 is selected from F or Cl;
R6 is H or an optional substituent;
Q is selected from O, CH2 or NR7 where R7 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
J is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, optionally interrupted by an ether linkage; and
A2 is optionally substituted and is selected from C6-10aryl and 5-10-membered heterocycles.
One embodiment provides a method for treating a Clostridium difficile infection comprising administration of a compound of Formula (I) to a patient with said infection
or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1-6alkyl and R3 is selected from H, OH, OC1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
Z is C or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
X is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles; and
R is optionally substituted and is selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles.
One embodiment provides a compound of formula (Ia)
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1-6alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
Z is C or N;
R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
R5 and R6 are independently selected from F or Cl;
X is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles; and
R is optionally substituted and is selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles.
One embodiment provides a compound of formula (II)
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1 alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
R5 is selected from F or Cl;
R6 is H or an optional substituent;
Z is C or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
Q is selected from O, CH2 or NR7 where R7 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
J is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, optionally interrupted by an ether linkage; and
A2 is optionally substituted and is selected from C6-10aryl and 5-10-membered heterocycles.
One embodiment provides a compound of formula (II)
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1-6alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
R5 is selected from F or Cl;
R6 is H or an optional substituent;
Z is C or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
Q is selected from O, S, CH2 or NR7 where R7 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
J is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, optionally interrupted by an ether linkage; and
A2 is optionally substituted and is selected from C6-10aryl and 5-10-membered heterocycles.
One embodiment provides a composition comprising a compound of Formula (I″), Formula (I) or Formula (II) or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof. In a particular embodiment the composition is a pharmaceutical composition and the salts are pharmaceutically acceptable. Preferably the pharmaceutical composition is for use in the treatment of a Clostridium difficile infection.
One embodiment provides a method for the treatment of a bacterial infection comprising administration of a compound of Formula (I″), Formula (I) or Formula (II) or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof to a patient with said infection. In a particular embodiment, the bacterial infection is a Clostridium difficile infection.
One embodiment provides a compound of Formula (I″), Formula (I) or Formula (II) or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof for treating a bacterial infection. In a particular embodiment the, bacterial infection is a Clostridium difficile infection.
One embodiment provides the use of a compound of Formula (I″), Formula (I) or Formula (II) or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof in the preparation of a medicament for the treatment of a bacterial infection in a subject (e.g., a patient). In a particular embodiment the, bacterial infection is a Clostridium difficile infection.
The present inventors have discovered a class of compounds with demonstrated activity against Clostridium difficile. The inventors have also discovered compounds with demonstrated activity against the hyper-virulent Clostridium difficile strain NAP1/BI/027 which has been associated with severe outbreaks of infection.
In one embodiment there is provided a method for treating a Clostridium difficile infection with a compound of Formula (I″), Formula (I) or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof wherein:
A ring is an optionally substituted phenyl;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1-6alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
X is an optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; and
R is optionally substituted and is selected from C3-8cycloalkyl, C6-10aryl, 4-10-membered heterocycles, or C6-12alkyl where C6-12alkyl may be straight chain or branched, saturated or unsaturated.
In another embodiment A ring is optionally substituted with one, two or three substituents independently selected from halo, hydroxyl, C1-3alkyl, C2-3alkenyl, C2-3alkynyl, C1-3alkoxyl, C1-3alkylhalo, C1-3alkoxylhalo, CN, NH2, NH(C1-3alkyl), N(C1-3alkyl)2 and NO2.
In one embodiment Y is CONR1R2.
In another embodiment R1 and R2 are each H.
In one embodiment R is an optionally substituted C6-10aryl or an optionally substituted 4-10-membered monocyclic or bicyclic heterocycle. Preferably R is optionally substituted and is selected from monocyclic C6aryl such as phenyl, bicyclic C10aryl such as naphthyl, a 5-membered monocyclic heterocycle, a 6-membered monocyclic heterocycle, a 9-membered bicyclic heterocycle and a 10-membered bicyclic heterocycle. Even more preferably R is an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl. Optionally substituted 5-membered monocyclic heteroaryls are particularly preferred.
Preferred optional substituents for R include but are not limited to one or more substituents independently selected from halo, hydroxyl, NO2, CN, C1-6alkyl such as methyl, ethyl and propyl, C2-6alkenyl such as ethenyl and propenyl, C2-6alkynyl such as ethynyl and propynyl, C1-6alkoxy such as methoxy, ethoxy and propoxy, haloC1-6alkyl such as CHF2 and CF3, haloC1-6alkoxy such as OCHF2 and OCF3, amino such as NH2, NH(C1-6alkyl) and N(C1-6alkyl)2, R4, C1-6alkyl-R4, C2-6alkenyl-R4, C2-6alkynyl-R4 where R4 is selected from C3-8cycloalkyl, C6-10aryl such as phenyl, 4-10-membered heterocycles such as 5-membered, 6-membered, 9-membered or 10-membered heterocycles, wherein each optional substituent having an available substitutable position may be further optionally substituted.
In one embodiment, R is optionally substituted with R4, C1 alkyl-R4, C2-6alkenyl-R4, or C2-6alkynyl-R4 which in each case may be further optionally substituted. Preferably R4 is a C6-10aryl such as phenyl or a 4-10-membered heterocycle such as 5-membered, 6-membered, 9-membered or 10-membered heterocycles. In a particular embodiment R is optionally substituted with halo, an optionally substituted phenyl, an optionally substituted 5-membered monocyclic heterocycle or an optionally substituted 6-membered heterocycle. In a further embodiment R is substituted with an optionally substituted phenyl, an optionally substituted 5-membered monocyclic heteroaryl including but not limited to pyrrolyl, pyrazolyl, imidazolyl, triazoyl, tetrazoyl, furanyl, oxazolyl, isooxazoyl, oxaziazolyl, thiophenyl, thiazolyl, isothiazoyl and thiadiazolyl or an optionally substituted 6-membered heteroaryl including but not limited to pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. R may be further optionally substituted with halo.
In another embodiment, when X is an optionally substituted C1 alkyl, C2-6alkenyl or C2-6alkynyl, suitable optional substituents include but are not limited to one or more substituents independently selected from hydroxyl, C1-6alkoxyl, CO2H, OP(═O)(OH)2, OP(═O)(OR5)2, P(═O)(OH)2, P(═O)(OR5)2, R6, OR6, CO2—R6, R6, OR5—CO2H, OR5—CO2R6, C(═O)—R6, NHC(═O)—R6, N(R5)C(═O)—R6, NHCO2—R6, N(R5)CO2—R6, OC(═O)NH—R6 or O(C═O)N(R6)2; where R5 is selected from C1 alkyl, C2-6alkenyl or C2-6alkynyl and R6 is selected from C1 alkyl, C2-6alkenyl, C2-6alkynyl, an amino group such as NH2, NH(R5), or N(R5)2; an alkylamino group such as C1-6alkylamino; a 5-6 membered monocyclic heterocycle or an alkylheterocycle group such as C1-6alkylheterocycle where the heterocycle preferably contains nitrogen; a 9-10 membered bicyclic heterocycle or C1-6alkylheterocycle wherein the heterocycle preferably contains nitrogen; or an aryl group such as phenyl or alkylaryl group such as C1-6alkylphenyl; wherein each optional substituent having an available substitutable position may be further optionally substituted.
In one embodiment X is an optionally substituted C1-6alkyl preferably an optionally substituted methyl, ethyl or propyl, even more preferably methyl. In a further embodiment, C1-6alkyl is unsubstituted.
In a particular embodiment the method comprises the administration of a compound of formula (Ib):
or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof wherein
B ring and C ring are each independently an optionally substituted phenyl, an optionally substituted 5-membered monocyclic heterocycle or an optionally substituted 6-membered heterocycle;
L represents a covalent bond or a C1-6alkylene, C2-6alkenylene or C2-6alkynylene moiety joining B ring and C ring; and
Y, A, Z and X are as previously defined for formula (I).
In a preferred embodiment, B ring is an optionally substituted 5-membered heteroaryl.
In another preferred embodiment C ring is an optionally substituted phenyl.
In still another preferred embodiment L is a covalent bond.
In a further embodiment the method comprises the administration of a compound of formula (Ic):
or a pharmaceutically acceptable salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof,
wherein Y1 and Y2 are independently selected from H, Cl, Br, I and F; R1 and R2 are each independently selected from H or optionally substituted C1-6alkyl, preferably H; X is H or optionally substituted C1-6alkyl and R is as previously defined according to formula (I) or is a α-L-C moiety defined according to formula (Ib).
In a further embodiment the method comprises the administration of a compound of formula (Id):
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein
A ring is optionally substituted with one or more substituents;
Y is selected from CONR1R2 and C(═NR3)NR1R2 where R1 and R2 are independently selected from H or optionally substituted C1 alkyl and R3 is selected from H, OH, OC1-6alkyl, OC(═O)C1-6alkyl, SO2C1-6alkyl or R3 joins together with R1 or R2 to form a —C(═O)—O— cyclic linking unit;
Z is C or N;
W is O or NR4 where R4 is H or is optionally substituted and selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles;
K contains an electrophilic carbonyl group and is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocyclyl.
A2 is optionally substituted and is selected from C6-10aryl and 5-10-membered heterocycles.
Compounds of Formula (Id) contain a linker K that bears an electrophilic carbonyl substituent. Without limitation by the theory, certain compounds of Formula (Id) may exhibit improved inhibitory properties of C. difficile that arise from a spatial arrangement wherein the proximity of the inhibitor molecule to a serine residue in the binding site permits the formation of a covalent hemiketal adduct.
In one embodiment the Clostridium difficile being treated is a drug resistant Clostridium difficile. In one embodiment the Clostridium difficile is Clostridium difficile (Isolate ID BI-9) and Clostridium difficile (Isolate ID 027-01).
The invention also provides methods for treating Clostridium difficile as described herein wherein the treatment is associated with less or lower disruption or suppression of normal bowel flora when compared to the administration of other antibacterials such as antibacterials used clinically including antibacterials used to treat Clostridium difficile (e.g., metronidazole and/or vancomycin).
The present inventors have also discovered a novel class of compounds per se with demonstrated activity against Clostridium difficile. Accordingly, in one embodiment there is provided a compound of formula (Ia)
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof,
wherein A, X, Y, Z, R and R4 are as previously defined.
The introduction of a non-hydrogen X group provides a chiral centre and accordingly, enantiomeric forms of the compounds of Formula (Ia).
In one embodiment there is provided an R-enantiomer of a compound of Formula (Ia) or a salt, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
In another embodiment there is provided an S-enantiomer of a compound of Formula (Ia) or a salt, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
In still another embodiment there is provided a mixture of R- and S-enantiomers of a compound of Formula (Ia) or a salt, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
In another embodiment there is provided a compound of formula (II)
or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof, wherein A, A2, Z, Y, W, Q, J, R6 and R5 are as previously defined.
In another embodiment, there is provided a compound of formula (II) or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof,
wherein
R6 is selected from CI or F.
In a preferred form, when there are one or more substituents there are one, two, three or four substituents or a range between any two of these integers.
In one embodiment, there is provided a compound selected from the group consisting of the compounds in Table 2 or Table 3 or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
The following embodiments are further provided. It is to be understood that these embodiments are for any Formula provided herein (e.g., Formula I″, I, II etc.) It is to be understood that two or more embodiments may be combined.
In one embodiment the A ring is optionally substituted with one, two or three substituents independently selected from halo, hydroxyl, C1-3alkyl, C2-3alkenyl, C2-3alkynyl, C1-3alkoxyl, C1-3alkylhalo, C1-3alkoxylhalo, CN, NH2, NH(C1-3alkyl), N(C1-3alkyl)2 and NO2.
In one embodiment the A ring is optionally substituted with one, two or three substituents independently selected from halo.
In one embodiment the A ring is optionally substituted with one, two or three substituents independently selected from halo and C1-3alkyl.
In one embodiment the A ring is optionally substituted with one, two or three substituents independently selected from halo and methyl.
In one embodiment the A ring is substituted at a position adjacent to the Y group with a halo and optionally substituted with one additional substituents independently selected from halo and C1-3alkyl.
In one embodiment the A ring is substituted independently at each position adjacent to the Y group with a halo.
In one embodiment the A ring is substituted independently at each position adjacent to the Y group with a fluoro.
In one embodiment the A ring is substituted independently at each position adjacent to the Y group with a fluoro or chloro.
In one embodiment the A ring is substituted independently at each position adjacent to the Y group with a fluoro or chloro.
In one embodiment the A ring is substituted only at the positions shown in the formula.
In one embodiment R5 is selected from F and Cl; R6 is H.
In one embodiment R5 is selected from F and Cl; R6 is H.
In one embodiment R5 and R6 are independently selected from F and Cl.
In one embodiment R5 is F.
In one embodiment R6 is F.
In one embodiment R6 is halo.
In one embodiment R6 is fluoro.
In one embodiment Y is CONR1R2.
In one embodiment R1 and R2 are each H.
In one embodiment R1 and R2 are each H or C1-6alkyl optionally substituted with NH2, NHCH3 or N(CH3)2. and R3 is H or OH.
In one embodiment R3 is OH.
In one embodiment Y is CONR1R2.
In one embodiment Y is CONH2, C(═N(OH))NH2 or CONHCH2NHCH3.
In one embodiment Y is CONH2, C(═N(OH))NH2, C(═N(H)NH2 or CONHCH2NHCH3.
In one embodiment Y is CONH2.
In one embodiment Z is CH.
In one embodiment Z is N.
In one embodiment W is O.
In one embodiment W is NH.
In one embodiment W is NR4 where R4 is H or is optionally substituted C1-12alkyl.
In one embodiment W is NR4 where R4 is H or is a C1-12alkyl optionally substituted with one or more groups selected from hydroxyl, nitrile, —CONRARB, (C1-C6)alkoxy, monocyclic heteroaryl and COORA, wherein the monocyclic heteroaryl is optionally substituted with one or more C1-C6alkyl groups and wherein RA and RB are independently hydrogen or a (C1-C6)alkyl.
In one embodiment W is NR4 where R4 is H, methyl, 2-hydroxyethyl, 3-cyanopropyl, 2-amino-2-oxoethyl, 2-methoxyethyl, 6-methylpyridin-3-yl, —CH2CO2H or —CH2CO2CH2CH3.
In one embodiment W is O or NH.
In one embodiment W is NH.
In one embodiment X is H or optionally substituted C1-12alkyl.
In one embodiment X is H or C1-12alkyl.
In one embodiment X is H or methyl.
In one embodiment X is H or C1-6alkyl optionally substituted with one or more groups selected from hydroxyl, C1-6alkoxyl, CO2H, OP(═O)(OH)2, OP(═O)(OR8)2, P(═O)(OH)2, P(═O)(OR8)2, R9, OR9, CO2—R9, OC(═O)—R9, OR8—CO2H, OR8—CO2R9, C(═O)—R9, NHC(═O)—R9, N(R8)C(═O)—R9, NHCO2—R9, N(R8)CO2—R9, OC(═O)NH—R9 or O(C═O)N(R9)2; where R8 is selected from C1-6alkyl, C2-6alkenyl or C2-6alkynyl and R9 is selected from C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, an amino group such as NH2, NH(R8), or N(R8)2; an alkylamino group such as C1-6alkylamino; a 5-6 membered monocyclic heterocycle or an alkylheterocycle group such as C1-6alkylheterocycle where the heterocycle preferably contains nitrogen; a 9-10 membered bicyclic heterocycle or C1-6 alkylheterocycle wherein the heterocycle preferably contains nitrogen; or an aryl group such as phenyl or alkylaryl group such as C1-6alkylphenyl; wherein each optional substituent having an available substitutable position may be further optionally substituted.
In one embodiment X is H or C1 alkyl optionally substituted with one or more groups selected from hydroxyl, C1-6alkoxyl, OP(═O)(OR8)2, OC(═O)—R9, OR8—CO2R9, OC(═O)NH—R9 or O(C═O)N(R9)2; where R8 is selected from C1-6alkyl, C2-6alkenyl or C2-6alkynyl and R6 is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, an amino group such as NH2, NH(R8), or N(R8)2; an alkylamino group such as C1-6alkylamino; a 5-6 membered monocyclic heterocycle or an alkylheterocycle group such as C1-6alkylheterocycle where the heterocycle preferably contains nitrogen; a 9-10 membered bicyclic heterocycle or C1-6alkylheterocycle wherein the heterocycle preferably contains nitrogen; or an aryl group such as phenyl or alkylaryl group such as C1-6alkylphenyl; wherein each optional substituent having an available substitutable position may be further optionally substituted.
In one embodiment X is H or C1-6alkyl optionally substituted with one or more groups selected from hydroxyl, C1-6alkoxyl, CO2H, OP(═O)(OH)2, OP(═O)(ORO8)2, P(—O)(OH)2, P(—O)(OR8)2, R9, OR9, CO2—R9, OC(═O)—R9, OR8—CO2H, OR8—CO2R9, C(═O)—R9, NHC(═O)—R9, N(R8)C(═O)—R9, NHCO2—R9, N(R8)CO2—R9, OC(═O)NH—R9 or O(C═O)N(R9)2; where R8 is selected from C1-6alkyl, C2-6alkenyl or C2-6alkynyl and R9 is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, an amino group such as NH2, NH(R8), or N(R8)2; an alkylamino group such as C1-6alkylamino; a 5-6 membered monocyclic heterocycle or an alkylheterocycle group such as C1-6alkylheterocycle where the heterocycle preferably contains nitrogen; a 9-10 membered bicyclic heterocycle or C1-6alkylheterocycle wherein the heterocycle preferably contains nitrogen; or an aryl group such as phenyl or alkylaryl group such as C1-6alkylphenyl; wherein each C1-6alkyl, C2-6alkenyl or C2-6alkynyl of R8 or R9 is optionally substituted with one or more groups selected from NH2, NH(R8), N(R8)2, hydroxyl, C1-6alkoxyl, CO2H, OP(═O)(OH)2, OP(═O)(OR8)2, P(═O)(OH)2, P(═O)(OR8)2, R9, OR9, CO2—R9, OC(═O)—R9, OR8—CO2H, OR8—CO2R9, C(═O)—R9, NHC(═O)—R9, N(R8)C(═O)—R9, NHCO2—R9, N(R8)CO2—R9, OC(═O)NH—R9 or O(C═O)N(R9)2, 5-6 membered monocyclic heterocycle and 9-10 membered bicyclic heterocycle wherein the 5-6 membered monocyclic heterocycle and 9-10 membered bicyclic heterocycle is optionally substituted with one or more C1-6alkyl, oxo or C1-6alkoxy.
In one embodiment X is H or C1-6alkyl optionally substituted with one or more groups selected from hydroxyl, C1-6alkoxyl, OP(═O)(OH)2, OP(═O)(OR8)2, OC(═O)—R9, OR8—CO2R9, C(═O)—R9, NHC(═O)—R9, N(R8)C(═O)—R9, NHCO2—R9, N(R8)CO2—R9, OC(═O)NH—R9 or O(C═O)N(R9)2; where R8 is selected from C1-6alkyl, C2-6alkenyl or C2-6alkynyl and R9 is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, an amino group such as NH2, NH(R8), or N(R8)2; an alkylamino group such as C1-6alkylamino; a 5-6 membered monocyclic heterocycle or an alkylheterocycle group such as C1-6 alkylheterocycle where the heterocycle preferably contains nitrogen; a 9-10 membered bicyclic heterocycle or C1-6alkylheterocycle wherein the heterocycle preferably contains nitrogen; or an aryl group such as phenyl or alkylaryl group such as C1-6alkylphenyl; wherein each C1-6alkyl, C2-6alkenyl or C2-6alkynyl of R8 or R9 is optionally substituted with one or more groups selected from NH2, NH(R8), N(R8)2, hydroxyl, C1-6alkoxyl, CO2H, OP(═O)(OH)2, OP(═O)(OR8)2, P(═O)(OH)2, P(═O)(OR8)2, R9, OR9, CO2—R9, OC(═O)—R9, OR8—CO2H, OR8—CO2R9, C(═O)—R9, NHC(═O)—R9, N(R8)C(═O)—R9, NHCO2—R9, N(R8)CO2—R9, OC(═O)NH—R9 or O(C═O)N(R9)2, 5-6 membered monocyclic heterocycle and 9-10 membered bicyclic heterocycle wherein the 5-6 membered monocyclic heterocycle and 9-10 membered bicyclic heterocycle is optionally substituted with one or more C1-6alkyl, oxo or C1-6alkoxy.
In one embodiment X is H or C1-6alkyl optionally substituted with one or more hydroxyl.
In one embodiment X is H or C1-6alkyl.
In one embodiment X is H methyl or hydroxylmethyl.
In one embodiment R is optionally substituted and is selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C6-10aryl and 4-10-membered heterocycles.
In one embodiment R is optionally substituted and is selected from C1-12alkyl, phenyl, naphthyl, a 5-membered monocyclic heterocycle, a 6-membered monocyclic heterocycle, a 9-membered bicyclic heterocycle and a 10-membered bicyclic heterocycle.
In one embodiment R is optionally substituted and is selected from phenyl and 5-6 membered monocyclic heteroaryl.
In one embodiment R is optionally substituted and is 5-6 membered monocyclic heteroaryl, 9-membered bicyclic heteroaryl or a 10-membered bicyclic heteroaryl.
In one embodiment R is optionally substituted and is selected from C2-12alkyl, C2-12alkenyl, C2-12alkynyl, thiazolyl, oxadiazolyl, oxazolyl, thiadiazolyl, pyrazolyl, thienyl, pyrimidinyl, pyridinyl, triazolyl, benzothiaxolyl and thiazolo[5,4-b]pyridine.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, hydroxyl, NO2, CN, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, R4, C1-6alkyl-R4, C2-6alkenyl-R4, C2-6alkynyl-R4 where R4 is selected from C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, SF5, NO2, CN, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, R4, C1-6alkyl-R4, C2-6alkenyl-R4, C2-6alkynyl-R4 where R4 is selected from C3-8cycloalkyl, C6-10aryl or 4-10-membered heterocycles wherein C6-10aryl is optionally substituted with one or more C1-6alkyl or SF5.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, R4, C1-6alkyl-R4, where R4 is selected from C6-10aryl and 4-10-membered heterocycles wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, SF5, C1-6alkoxy, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, R4, where R4 is selected from C6-10aryl optionally substituted with one or more C1-6alkyl or SF5.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, —SC1-6alkyl, R4, C1-6alkyl-R4, where R4 is selected from phenyl, pyrimidinyl, oxazolyl, oxadiazolyl, thienyl, thiazolyl, and benzothiazolyl wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, SF5, C1-6alkoxy, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, CO2C1-6alkyl, and phenyl optionally substituted with one or more halo, C1-6alkyl, haloC1-6alkoxy or SF5.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 alkoxy, R4, C1-6alkyl-R4, where R4 is selected from phenyl, pyrimidinyl, oxazolyl, oxadiazolyl, thienyl, thiazolyl, and benzothiazolyl wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, SF5, C1-6alkoxy, C1-6alkyl, haloC1-6 alkyl, haloC1-6alkoxy, CO2C1-6alkyl, and phenyl optionally substituted with one or more halo, C1-6alkyl, haloC1-6alkoxy or SF5.
In one embodiment R is selected from C2-12alkyl, C2-12alkenyl, C2-12alkynyl, thiazolyl, oxadiazolyl, oxazolyl, thiadiazolyl, pyrazolyl, thienyl, pyrimidinyl, pyridinyl, triazolyl, benzothiaxolyl and thiazolo[5,4-b]pyridine each of which is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, R4, C1-6alkyl-R4, where R4 is selected from phenyl, pyrimidinyl, oxazolyl, oxadiazolyl, thienyl, thiazolyl, and benzothiazolyl wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, SF5, C1-6alkoxy, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, CO2C1-6alkyl, and phenyl optionally substituted with one or more halo, C1-6alkyl, haloC1-6alkoxy or SF5.
In one embodiment R is selected from C1-12alkyl, phenyl, a 5-membered monocyclic heterocycle, a 6-membered monocyclic heterocycle, a 9-membered bicyclic heterocycle and a 10-membered bicyclic heterocycle each of which is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, R4, C1-6alkyl-R4, where R4 is selected from phenyl, pyrimidinyl, oxazolyl, oxadiazolyl, thienyl, thiazolyl, and benzothiazolyl wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, SF5, C1-6alkoxy, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, CO2C1-6alkyl, and phenyl optionally substituted with one or more halo, C1-6alkyl, haloC1-6alkoxy or SF5.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, hydroxyl, NO2, CN, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, R4, C1-6alkyl-R4, C2-6alkenyl-R4, C2-6alkynyl-R4 where R4 is selected from C3-8cycloalkyl, C6-10aryl and 4-10-membered heterocycles wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, hydroxyl, NO2, CN, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, R4, C1-6alkyl-R4, C2-6alkenyl-R4, C2-6alkynyl-R4 where R4 is selected from C3-8cycloalkyl, C6-10aryl or 4-10-membered heterocycles wherein C6-10aryl is optionally substituted with one or more C1-6alkyl.
In one embodiment R is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, R4, C1-6alkyl-R4, where R4 is selected from C6-10aryl and 4-10-membered heterocycles wherein each optional substituent having an available substitutable position may be further optionally substituted with one or more groups selected from halo, C1-6alkoxy, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, R4, where R4 is selected from C6-10aryl optionally substituted with one or more C1-6alkyl.
In one embodiment R is an optionally substituted with (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, hydroxy, hydroxy(C1-C6)alkyl, (C1-C3)alkoxy(C1-C3)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, halo, fully or partially fluorinated (C1-C3)alkyl, (C1-C3)alkoxy or (C1-C3)alkylthio, nitro, nitrile (—CN), oxo (═O), thiols, alkylthiols, trialkylsilyl, diarylalkylsilyl, trialkylsilyloxy, diarylalkylsilyloxy, dialkylphosphonyl, dialkoxyphosphonyl, diarylphosphonyl, diaryloxyphosphonyl, alkylphosphinyl, arylphosphinyl, alkoxyphosphinyl, aryloxyphosphinyl, dialkyoxyphoshoryl, diaryloxyphosphoryl, phosphoryl, phosphinyl, phenyl, phenyl(C1-C3)alkyl-, phenoxy, monocyclic heteroaryl, heteroaryl(C1-C3)alkyl-, or heteroaryloxy with 5 or 6 ring atoms, cycloalkyl having 3 to 6 ring carbon atoms, —COORA, —CORA, —OCORA, —SO2RA, —CONRARB, —CONHNH2, —S2NRARB, SF5, —NRARB, —NHNH2, —OCONRARB, —NRBCORA, —NRBCOORA, —NRBSO2ORA or —NRACONRARB wherein RA and RB are independently hydrogen or a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or (C1-C3)alkoxy(C1-C3)alkyl group or, in the case where RA and RB are linked to the same N atom, RA and RB taken together with that nitrogen may form a cyclic amino ring such as morpholinyl, piperidinyl, piperazinyl, or 4-(C1-C6)alkyl-piperizinyl, wherein each optional alkyl, cycloalkyl, alkylaryl, aryl, heterocyclyl, or heteroaryl substituent may also be optionally substituted.
In one embodiment R is an optionally substituted with (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, halo, phenyl, phenyl(C1-C3)alkyl-, phenoxy, monocyclic heteroaryl, heteroaryl(C1-C3)alkyl-, or heteroaryloxy with 5 or 6 ring atoms, wherein each optional alkyl, alkylaryl, aryl, heterocyclyl, or heteroaryl substituent may also be optionally substituted.
In one embodiment R is optionally substituted and is selected from C1-12alkyl, and 4-10-membered heterocycles.
In one embodiment R is optionally substituted and is selected from C1-12alkyl, and 5-membered heteroaryl.
In one embodiment R is an optionally substituted with (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, hydroxy, hydroxy(C1-C6)alkyl, (C1-C3)alkoxy(C1-3)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, halo, fully or partially fluorinated (C1-C3)alkyl, (C1-C3)alkoxy or (C1-C3)alkylthio, nitro, nitrile (—CN), oxo (═O), thiols, alkylthiols, trialkylsilyl, diarylalkylsilyl, trialkylsilyloxy, diarylalkylsilyloxy, dialkylphosphonyl, dialkoxyphosphonyl, diarylphosphonyl, diaryloxyphosphonyl, alkylphosphinyl, arylphosphinyl, alkoxyphosphinyl, aryloxyphosphinyl, dialkyoxyphoshoryl, diaryloxyphosphoryl, phosphoryl, phosphinyl, phenyl, phenyl(C1-C3)alkyl-, phenoxy, monocyclic heteroaryl, heteroaryl(C1-C3)alkyl-, or heteroaryloxy with 5 or 6 ring atoms, cycloalkyl having 3 to 6 ring carbon atoms, —COORA, —CORA, —OCORA, —SO2RA, —CONRARB, —CONHNH2, —SO2NRARB, SF5, —NRARB, —NHNH2, —OCONRARB, —NRBCORA, —NRBCOORA, —NRBSO2ORA or —NRACONRARB wherein RA and RB are independently hydrogen or a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or (C1-C3)alkoxy(C1-C3)alkyl group or, in the case where RA and RB are linked to the same N atom, RA and RB taken together with that nitrogen may form a cyclic amino ring such as morpholinyl, piperidinyl, piperazinyl, or 4-(C1-C6)alkyl-piperizinyl, wherein each optional substituent may also be optionally substituted.
In one embodiment R is an optionally substituted with one or more halo, phenyl, phenoxy, or heteroaryloxy with 5 or 6 ring atoms, wherein each phenoxy, phenoxy or heteroaryloxy is optionally substituted with one or more fully or partially fluorinated (C1-C3)alkyl or fully or partially fluorinated (C1-C3)alkoxy.
In one embodiment a compound of Formula Ia is a compound of compound number 122, 123, 150, 152, 179-187 or 212 or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
In one embodiment a compound of Formula Ia is a compound of compound number 122 or 123.
In one embodiment Q is selected from O or NR7 where R7 is H.
In one embodiment Q is O.
In one embodiment Q is CH2.
In one embodiment Q is selected from O, NH or CH2.
In one embodiment J is an optionally substituted linker selected from C1-12alkyl, C2-12alkenyl and C2-12alkynyl, wherein the linker is interrupted by an ether linkage.
In one embodiment J is a linker selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, interrupted by an ether linkage.
In one embodiment J is an optionally substituted C1-12alkyl or C2-12alkynyl.
In one embodiment J is C1-12alkyl, interrupted by an ether linkage.
In one embodiment J is C1-12alkyl or C2-12alkynyl each interrupted by an ether linkage.
In one embodiment J is C1-12alkyl or C2-12alkynyl.
In one embodiment J is an optionally substituted linker selected from C1-12alkyl and C2-12alkynyl.
In one embodiment J is C1-12alkyl, optionally interrupted by an ether linkage.
In one embodiment A2 is an optionally substituted C6-10aryl.
In one embodiment A2 is an optionally substituted phenyl.
In one embodiment A2 is an optionally substituted 5-10-membered heterocycle.
In one embodiment A2 is an optionally substituted phenyl, pyridinyl or pyrimidinyl.
In one embodiment A2 is an optionally substituted with (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, hydroxy, hydroxy(C1-C6)alkyl, (C1-C3)alkoxy(C1-C3)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, halo, fully or partially fluorinated (C1-C3)alkyl, (C1-C3)alkoxy or (C1-C3)alkylthio, nitro, nitrile (—CN), oxo (═O), thiols, alkylthiols, trialkylsilyl, diarylalkylsilyl, trialkylsilyloxy, diarylalkylsilyloxy, dialkylphosphonyl, dialkoxyphosphonyl, diarylphosphonyl, diaryloxyphosphonyl, alkylphosphinyl, arylphosphinyl, alkoxyphosphinyl, aryloxyphosphinyl, dialkyoxyphoshoryl, diaryloxyphosphoryl, phosphoryl, phosphinyl, phenyl, phenyl(C1-C3)alkyl-, phenoxy, monocyclic heteroaryl, heteroaryl(C1-C3)alkyl-, or heteroaryloxy with 5 or 6 ring atoms, cycloalkyl having 3 to 6 ring carbon atoms, —COORA, —CORA, —OCORA, —SO2RA, —CONRARB, —CONHNH2, —SO2NRARB, SF5, —NRARB, —NHNH2, —OCONRARB, —NRBCORA, —NRBCOORA, —NRBSO2ORA or —NRACONRARB wherein RA and RB are independently hydrogen or a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or (C1-C3)alkoxy(C1-C3)alkyl group or, in the case where RA and RB are linked to the same N atom, RA and RB taken together with that nitrogen may form a cyclic amino ring such as morpholinyl, piperidinyl, piperazinyl, or 4-(C1-C6)alkyl-piperizinyl.
In one embodiment A2 is an optionally substituted with (C1-C6)alkyl, (C1-C6)alkoxy, halo, —CN, fully or partially fluorinated (C1-C3)alkyl, (C1-C3)alkoxy or (C1-C3)alkylthio, or SF5.
In one embodiment A2 is an optionally substituted with halo, —CN, fully or partially fluorinated (C1-C3)alkyl, fully or partially fluorinated (C1-C3)alkoxy or SF5.
In one embodiment A2 is an optionally substituted with halo, fully or partially fluorinated (C1-C3)alkyl, fully or partially fluorinated (C1-C3)alkoxy or SF5.
In one embodiment a compound of Formula Ia is a compound of compound number 124-187 or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
In one embodiment a compound of Formula Ia is a compound of compound number 136, 145, 146, 156 or 161 or a salt, racemate, isomer, diastereoisomer, enantiomer, hydrate, solvate, N-oxide, pharmaceutically acceptable derivative or prodrug thereof.
As used herein, the term “halo” or “halogen” refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo).
As used herein, the term “alkyl” either used alone or in compound terms such as NH(alkyl) or N(alkyl)2, refers to monovalent straight chain or branched hydrocarbon groups, having 1 to 3, 1 to 6 or 1 to 12 carbons as appropriate. Each C1-6alkyl group is preferably C1, C2 or C3 alkyl, i.e. C1-3alkyl. For example, suitable alkyl groups include, but are not limited to methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 2-, 3- or 4-methylpentyl, 2-ethylbutyl, n-hexyl or 2-, 3-, 4- or 5-methylpentyl.
The term “haloalkyl” refers to an alkyl group which has one or more halo substituents. One, two or three halo substituents are particularly preferred. For instance, CF3 is a haloalkyl group as is CHF2.
As used herein, the term “alkenyl” refers to a straight chain or branched hydrocarbon groups having one or more double bonds between carbon atoms. Suitable alkenyl groups include, but are not limited to, ethenyl, allyl, propenyl, iso-propenyl, butenyl, pentenyl and hexenyl. Each C2-6alkynyl group is preferably C2 or C3 alkynyl, i.e. C2-3alkynyl.
As used herein, the term “alkynyl” refers to a straight chain or branched hydrocarbon groups having one or more triple bonds between carbon atoms. Each C2-6alkenyl group is preferably C2 or C3 alkyl, ie C2-3alkyl.
The terms “cycloalkyl”, “carbocyclic” and “carbocyclyl” as used herein, refers to cyclic hydrocarbon groups. Suitable cycloalkyl groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term “aryl” as used herein, refers to a C6-C10 aromatic hydrocarbon group, for example phenyl or naphthyl.
The term “alkylaryl” includes, for example, benzyl.
The terms “heterocycle”, “heterocyclic” and “heterocyclyl” when used alone or in compound words includes monocyclic, polycyclic, fused or conjugated hydrocarbon residues wherein one or more carbon atoms (and where appropriate, hydrogen atoms attached thereto) are replaced by a heteroatom so as to provide a non-aromatic residue. The bonds between atoms may be saturated or unsaturated. Suitable heteroatoms include O, N and S. Where two or more carbon atoms are replaced, this may be by two or more of the same heteroatom or by different heteroatoms. Suitable examples of heterocyclic groups may include azetidine, pyrrolidinyl, piperidyl, piperazinyl, azepane, morpholino, quinolinyl, isoquinolinyl, thiomorpholino, dioxanyl, 2,2′-dimethyl-[1,3]-dioxolanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrrolyl, cyclic sulfonamides such as sultams etc. The term heterocyclyl will be understood to encompass heteroaromatic/heteroaryl ring systems.
The term “heteroaromatic” or “heteroaryl” may be used interchangeably and includes but is not limited to a 5- or 6-membered heteroaromatic ring containing one or more heteroatoms selected from O, N and S. Suitable examples of heteroaryl groups include 5-membered heteroaryls such as furanyl, thiophenyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thioazolyl, isothiazolyl, thiodiazolyl, etc and 6-membered heteroaryls such as pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, etc. The heteroaromatic ring may be fused to a 5- or 6-membered aromatic or heteroaromatic ring to form an 8-10 membered bicyclic aromatic ring system eg benzofuran, pyrrolopyrimidine, furopyridine, benzothiazole, benzisothiazole, benzoxazole, benzisoxazole, benzimidazole, benztriazole, benzothiophene, oxazolopyridine, imidazopyridine, thiazolopyridine, quinoline, isoquinoline, indazole, indole, isoindole, etc.
The term “leaving group” will be understood by the skilled person and means a molecular fragment which is capable of being displaced as a stable species taking it with it the bonding electrons. Leaving groups are used in organic chemistry to facilitate covalent bonding between two moieties. The term “leaving group” includes but is not limited to, halo groups (such as iodo, bromo, and chloro) or sulfonate ester groups such as mesylate, tosylate, osylate, nosylate, or besylate.
Unless otherwise stated, each alkyl, cycloalkyl, alkylaryl, aryl, heterocyclyl, or heteroaryl group may be optionally substituted with, for example, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, hydroxy, hydroxy(C1-C6)alkyl, (C1-C3)alkoxy(C1-C3)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, halo (including fluoro, bromo and chloro), fully or partially fluorinated (C1-C3)alkyl, (C1-C3)alkoxy or (C1-C3)alkylthio such as trifluoromethyl, trifluoromethoxy, and trifluoromethylthio, nitro, nitrile (—CN), oxo (═O), thiols, alkylthiols, trialkylsilyl, diarylalkylsilyl, trialkylsilyloxy, diarylalkylsilyloxy, dialkylphosphonyl, dialkoxyphosphonyl, diarylphosphonyl, diaryloxyphosphonyl, alkylphosphinyl, arylphosphinyl, alkoxyphosphinyl, aryloxyphosphinyl, dialkyoxyphoshoryl, diaryloxyphosphoryl, phosphoryl, phosphinyl, phenyl, phenyl(C1-C3)alkyl-, phenoxy, monocyclic heteroaryl, heteroaryl(C1-C3)alkyl-, or heteroaryloxy with 5 or 6 ring atoms, cycloalkyl having 3 to 6 ring carbon atoms, —COORA, —CORA, —OCORA, —SO2RA, —CONRARB, —CONHNH2, —SO2NRARB, SF5, —NRARB, —NHNH2, —OCONRARB, —NRBCORA, —NRBCOORA, —NRBSO2ORA or —NRACONRARB wherein RA and RB are independently hydrogen or a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or (C1-C3)alkoxy(C1-C3)alkyl group or, in the case where RA and RB are linked to the same N atom, RA and RB taken together with that nitrogen may form a cyclic amino ring such as morpholinyl, piperidinyl, piperazinyl, or 4-(C1-C6)alkyl-piperizinyl such as 4-methyl-piperazinyl. In a preferred form, each alkyl, cycloalkyl, alkylaryl, aryl, heterocyclyl, or heteroaryl group may be optionally substituted with one or more of C1-C3alkyl, C3-C6cycloalkyl, C6aryl, heterocyclyl, heteroaryl, C1-C3alkylOH, alkylaryl, OH, OC1-C3alkyl, halo, CN, NO2, CO2H, CO2C1-C3alkyl, CONH2, CONH(C1-C3alkyl), C(O)N(C1-C3alkyl)2, haloC1-3alkyl such as CF3 and CHF2, haloC1-3alkoxy such as OCHCF2 and OCF3, ═O, SF5, C(O)C1-3alkyl, C(O)haloC1-3alkyl, NH2, NH(C1-C3alkyl) or N(C1-C3alkyl)2. For example, an optionally substituted aryl group may be 4-methylphenyl or 4-hydroxyphenyl group, and an optionally substituted alkyl group may be 2-hydroxyethyl, trifluoromethyl, or difluoromethyl. Each optional alkyl, cycloalkyl, alkylaryl, aryl, heterocyclyl, or heteroaryl substituent may also be optionally substituted.
In a preferred form, where a group is substituted by an optional substituent, there are 1 to 4 optional substituents, 1 to 3 optional substituents, 1 to 2 optional substituents, or 1 optional substituent.
Examples of optional substituents also include suitable oxygen and nitrogen protecting groups (see “Greene's Protective Groups in Organic Synthesis” Peter G. M. Wuts and Theodora W. Greene, Fourth Edition, Wiley, 2006).
The salts of the compounds are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts.
Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, malic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.
Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, zinc, ammonium, alkylammonium such as salts formed from triethylamine, alkoxyammonium such as those formed with ethanolamine and salts formed from ethylenediamine, choline or amino acids such as arginine, lysine or histidine. General information on types of pharmaceutically acceptable salts and their formation is known to those skilled in the art and is as described in general texts such as “Handbook of Pharmaceutical salts” P. H. Stahl, C. G. Wermuth, 1st edition, 2002, Wiley-VCH.
Basic nitrogen-containing groups may be quarternised with such agents as lower alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.
Hydroxyl groups may be esterified with groups including lower alkyl carboxylic acids, such as acetic acid and 2,2-dimethylpropionic acid, or sulfonated with groups including alkyl sulfonic acids, such as methyl sulfonic acid.
It will be recognized that the compounds are likely to possess asymmetric centers (particularly about the carbon of which X or X1 is a substituent) and are therefore capable of existing in more than one stereoisomeric form. The invention thus also relates to compounds in substantially pure isomeric form at one or more asymmetric centers e.g., greater than about 90% ee, such as about 95% or 97% ee or greater than 99% ee, as well as mixtures, including racemic mixtures, thereof. Such isomers may be prepared by asymmetric synthesis, for example using chiral intermediates, or by chiral resolution. In a one embodiment, the stereochemistry around the carbon substituted with X or X1 is R. In another embodiment, the stereochemistry around the carbon substituted with X or X1 is S.
This invention also encompasses prodrugs of the compounds. Compounds having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined to free amino, hydroxy and carboxylic acid groups of the compounds. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvlin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of the compounds through hydroxyl, amine or carbonyl functionalities. Prodrugs also include phosphate derivatives of compounds (such as acids, salts of acids, or esters) joined through a phosphorus-oxygen bond to a free hydroxyl of the compounds.
Other prodrugs include esters or peptides formed respectively between hydroxyl groups or amine groups of the compounds.
The compounds of the present invention may be administered by any suitable means, for example, orally, parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions).
In a preferred embodiment the administration is intravenous administration, oral administration or a combination thereof.
There is also provided a composition comprising a compound of the present invention. Preferably, the composition further comprises a pharmaceutically acceptable carrier, diluent or excipient.
The compositions of the present invention may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
Pharmaceutical formulations include those for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, together with a conventional adjuvant, carrier or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids as solutions, suspensions, emulsions, elixirs or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.
However, the method can also be practiced in other species, such as avian species (e.g., chickens).
The subjects treated in the above method are mammals, including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species, and preferably a human being, male or female.
The term “effective amount” means the amount of the subject composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The terms “administration of” and or “administering a” compound should be understood to mean providing a compound of the invention to the individual in need of treatment.
The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
It is to be understood that a patient can be a mammal such as a human.
The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
In the treatment or prevention of bacterial infections, an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The pharmaceutical compositions and methods of the present invention may further comprise other therapeutically active compounds which are usually applied in the treatment of bacterial infections. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
Accordingly, in one aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of Formula (I″), Formula (I) or Formula (II) and a further antibacterial agent.
In another aspect of the present invention, there is provided a method of treating a bacterial infection comprising administering a compound of Formula (I″), Formula (I) or Formula (II) together with a further antibacterial agent wherein said compound of Formula (I″), Formula (I) or Formula (II) and said antibacterial agent are administered in either order and can be administered simultaneously or sequentially.
Said further antibacterial agent may be selected from the group consisting of those indicated for the treatment of Clostridium difficile infections, including but not limited to for example, vancomycin, metronidazole and fidaxomicin, etc.
When other therapeutic agents are employed in combination with the compounds of the present invention they may be used for example in amounts as noted in the Physician Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
Compounds of Formula (I) or Formula (II) may generally be prepared by coupling a compound of Formula (III) with a compound of Formula (IV) or (V) under the following conditions
wherein A, A2, J, Q, X1, Y, Z and R are as previously defined and LG is a leaving group. To a solution of (IV) or (V) (approximately 1.0 eq) in an organic solvent such as DMF is added a base such as K2CO3 (approximately 2.0 eq) followed by (III) (approximately 1.0 eq). The resulting reaction mixture is stirred under a N2 atmosphere at room temperature. After completion of the reaction the product is extracted into an organic solvent such as EtOAc and purified by silica gel chromatography. Alternatively, where LG is OH, triphenylphosphine (approximately 1.2 eq) is dissolved in a suitable solvent such as THF and treated with diethylazodicarboxylate (approximately 1.2 eq) at 0° C. After stirring for a short time a solution of (III) (1 eq), (IV) or (V) (1 eq) and TEA (1.1 mL, 1 eq) in the same solvent is added to the initial mixture and allowed to warm to room temperature. After completion of the reaction, the mixture may be concentrated and purified by silica chromatography.
It will be understood by those skilled in the art that a considerable diversity of compounds of Formula (I) may be accessed by post-synthetic modification of the R group by means of variation of an α-halo ketone building block. Accordingly, the succeeding methods, which are generally described for the synthesis of compounds of Formula (I), utilise an α-halo ketone as a starting material or precursor intermediate.
An extensive selection of α-bromo and α-chloro ketones is available from commercial suppliers. Alternatively, a further diversity of α-bromo ketones may be prepared according to one or more the following standard methods.
One Pot Conversion of a Substituted Carboxylic Acid to an α-Bromo Ketone
To an ice-cold solution of a substituted carboxylic acid (1.0 eq) in an inert solvent (such as dichloromethane) is added oxalyl chloride (5.0 eq) and DMF (catalytic amount). The resulting reaction mixture is stirred at room temperature. When the reaction is complete, the mixture is concentrated under inert atmosphere to obtain the crude product, which is then dissolved in diethyl ether, cooled to 0° C. and treated with TMS-diazomethane (1.50 eq). The resulting solution is stirred at 0° C. for 30 minutes, followed by addition of HBr (47% aq solution). After completion of reaction, water is added to the mixture and the product extracted into EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the purified α-bromo ketone, typically in low yield.
A solution of optionally substituted heteroaryl bromide (1.0 eq) and ethoxyvinyl tri-n-butyltin (1.50 eq) in DMF is purged with nitrogen for 15 minutes followed by addition of tetrakis(triphenylphosphine)palladium (0.10 eq). The resulting solution is again purged with nitrogen for 15 minutes and then heated to approximately 110° C. for 2 h. After the completion of reaction, ice-cold water is added to the reaction mixture, which is then washed with EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the pure enol ether, typically in good yields. If this product hydrolyses spontaneously to a methyl ketone, it may be converted to the desired α-methyl ketone by one of the methods described below. In all other cases, an ice-cold solution of the enol ether (1.0 eq) in THF-H2O (3:1) is treated with NBS (1.0 eq) and stirred at room temperature for 30 minutes. After the completion of reaction water is added to the mixture, which is then washed with EtOAc (3 times). The combined organics are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the purified α-bromo ketone.
Preparation of an α-Bromo Ketone by Bromination of a Methyl Ketone
Approach i):
To a solution of a substituted methyl ketone (1.0 eq) in THF is added tetrabutylammonium tribromide (1.0 eq) and the resulting reaction mixture heated at reflux for 2 h. After completion of reaction, water is added to the mixture and the product extracted into EtOAc (3 times). The combined organics are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the purified α-bromo ketone, typically in good yield.
Approach ii):
A solution of substituted methyl ketone (1.0 eq) in glacial acetic acid is cooled to 0° C. and treated drop-wise with bromine (1.0 eq). A catalytic amount of HBr in acetic acid is added to the reaction mixture and allowed to stir at room temperature typically for 10-20 h. After the completion of reaction, the mixture is cooled to 0° C. and quenched with ice-cold water, followed by extraction with EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the purified α-bromo ketone, typically in 20-40% yield.
Approach iii):
A solution of substituted methyl ketone (1.0 eq) in THF and 5,5-dibromobarbituric acid (0.90 eq) is heated at reflux, typically for 10-20 h. After completion of the reaction, water is added to the mixture, which is then washed with EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the purified α-bromo ketone, typically in good yield.
Many methyl ketones are available commercially and are suitable for bromination according to the foregoing methods. In addition to commercially-sourced materials, further methyl ketones may be prepared by the following method.
To a solution of substituted carboxylic acid (1.0 eq) in DMF is added N,O-dimethylhydroxylamine hydrochloride (1.10 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.50 eq), 1-hydroxybenzotriazole (1.0 eq), 4-dimethylaminopyridine (1.0 eq) and a catalytic amount of triethylamine. The resulting reaction mixture is stirred at room temperature. After the completion of reaction (TLC monitoring), ice-cold water is added to the reaction mixture, which is then extracted with EtOAc (3 times). The combined organics are washed with ice-cold water and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. If required, the crude product may be purified by silica chromatography (typically eluted with EtOAc/hexane). A solution of the above Weinreb amide (1.0 eq) in THF is cooled to 0° C. and treated with methylmagnesium bromide (2.0 eq). The resulting reaction mixture is stirred at 0° C. for approximately 45 minutes. At the completion of reaction (TLC monitoring), saturated ammonium chloride solution is added to the reaction mixture, followed by extraction with EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (typically eluted with EtOAc/hexane) to obtain the pure methyl ketone.
One general method for the preparation of compounds of Formula (I) is described in Scheme 1.
Step 1: Formation of Oxazole/Thiazole Ring; Coupling of Halomethyl Ketones with Amide/Thioamide Derivatives
A mixture of α-halo ketone C-L-B—C(O)—CH-halo (1.0 eq) and amide/thioamide derivative X1—CH2—C(X)NH2 (2.50 eq) is heated at 120-130° C. for 2-3 h. After completion of reaction, water is added to the reaction mass and washed with EtOAc. The combined organics are collected, washed sequentially with water and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue may be purified by silica chromatography (EtOAc/hexane) to obtain the desired products, typically in moderate to good yields.
Approach i):
To a solution of the 5-H oxazolyl or thiazolyl substrate (1.0 eq) in acetic acid (˜5 mL/mmol) is added NBS or NCS (1.0 eq) and the resulting reaction mixture is stirred at room temperature for 30-45 minutes. After the completion of reaction (TLC monitoring), the reaction mass is diluted with water, basified with saturated sodium bicarbonate solution and extracted with EtOAc. The combined organics are washed with brine, dried, filtered and concentrated. The residue may be purified over silica gel to obtain the desired products, typically in moderate yields.
Approach ii):
To an ice-cold solution of a 5-H oxazole derivative (1.0 eq) in DCM (˜10 mL/mmol) is added a stock solution of 1M bromine in DCM (1.0 eq) and the resulting solution is stirred at room temperature for 5-6 h while constantly monitoring the progress of the reaction by TLC/MS. After the majority of the starting material is converted to product, the reaction is quenched by addition of saturated aqueous NaHCO3 solution followed by extraction with EtOAc (3 times). The combined organics are washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material may be purified by flash chromatography (EtOAc-hexane) to obtain the desired product, typically in good yield.
To a solution of the starting material (1.0 eq) in CCl4 is added NBS (1.0 eq) and AIBN (0.10 eq). The resulting reaction mixture is stirred at 80° C. for 5-6 h. After the completion of reaction (TLC monitoring), the reaction mixture is filtered and concentrated. The crude residue may be purified over silica gel to obtain the pure alkyl halide, typically in moderate yield.
To a solution of the appropriate alkyl halide (1.0 eq) in DMF is added K2CO3 (2.0 eq) followed by 2,6-difluoro-3-hydroxybenzamide (1.0 eq). The resulting reaction mixture is stirred under N2 atmosphere at room temperature for 2 h. After the reaction is complete (TLC monitoring), ice-cold water is added to the reaction mixture and extracted with EtOAc (3 times). The combined organics are washed with 1M NaOH solution, water and brine, dried (Na2SO4), filtered and concentrated. The crude residue may be purified by silica chromatography to obtain the desired product, typically in moderate to good yields.
One general method for the preparation of compounds of Formula (I) where X1 is a hydroxyl or hydroxyalkyl moiety is described in Scheme 2.
Step 1: Ring formation as per step 1 General Method A.
Step 2: Halogenation as per step 3 General Method A.
Step 3: Coupling as per step 4 General Method A.
Step 4: Reduction of the ester/keto group
To an ice cold solution of the corresponding ester derivative (1.0 eq) in MeOH is added NaBH4 (3.0 eq) portion wise and the resulting reaction mixture is refluxed for 2 h. After the completion of reaction (TLC monitoring), water is added to the mixture and extracted with EtOAc (3 times). The combined organics are washed with water, brine, dried (Na2SO4), filtered and concentrated to obtain the desired product (in good to excellent yields), typically without need for further purification.
In an alternative method the carboxylate produced following step 1 may be converted to a hydroxyl then protected as an acetate during functional group interconversions of substituents on ring B or ring C then deprotected to the hydroxyl following coupling to the benzamide head group.
One general method for the preparation of compounds of Formula (I) wherein X1 is a carboxylate moiety, e.g. carboxylic acid, esters, acetates, is described in Scheme 3.
To a solution of the starting material having the primary hydroxyl group in DCM is added a suitable base such as imidazole (1.20 eq) and an acylating agent, such as an activated ester, an alkyl halide or an anhydride (1.20 eq). The resulting reaction mixture is stirred at room temperature. After the completion of reaction (TLC monitoring), water is added followed by extraction with EtOAc (3 times). The combined organics are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue may be purified by chromatography to obtain the desired product.
Alternatively oxidation conditions such as CrO3, H2SO4, acetone (Jones Reagent) may be employed to form carboxylates from starting materials having the primary hydroxyl group. Other suitable acylating or oxidizing reagents and conditions will be familiar to the skilled person.
One general method for the preparation of compounds of Formula (Id) is described in Scheme 4.
10% NaOH; c) i) NMM, IBCF, THF, −10° C.; ii) NaBH4, H2O, 0° C.; d) COCI2, DMSO, Et3N, CH2Cl2; e) 1,3-benzothiazole, BuLi, THF, −78° C.; f) Dess-Martin periodinane, CH2Cl2; g) TMSCN; h) NH2OH, EtOH; j) ArCO2H, DCC, then pyridine, 120° C.; k) Burgess reagent; 1) TFA, CH2Cl2; m) i) K2CO3, MeOH; ii) Dess-Martin periodinane, CH2Cl2.
The skilled person will appreciate that a wide diversity of compounds may be provided by functional group interconversions of hydroxyls and carboxylates including but not limited to halogens, ethers, ketones, carboxylic acids, esters, carbonates, amines, amides, ureas, carbamates, sulfates, sulfonamides, phosphates, heterocycles, heteroaryls, optionally substituted alkyl chain extensions and so on. Embodiments will now be described.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention will now be described without limitation by reference to the examples which follow.
1H NMR spectra were recorded on a Bruker Ultrashield™ 400 spectrometer. Spectra were recorded in CDCl3, d6-acetone, CD3CN, CD3OD or d6-DMSO using the residual solvent peak as a reference. Chemical shifts are reported on the δ scale in parts per million (ppm) using the following conventions to assign the multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and the prefix br (broad). Mass spectra (ESI) were typically recorded on a Thermo Finnigan LCQ Advantage or LCQ Deca mass spectrometer coupled with a Thermo Finnigan Surveyor HPLC system. The HPLC was performed using Waters Acquity UPLC BEH or Phenomenex C8(2) or C18(2) columns. Water containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B) were used for separations at acidic pH. Ammonium acetate (5 mM, solvent A) and methanol or acetonitrile (solvent B) were used for separations at neutral pH. Flash chromatography was performed on 40-63 μm or 125-250 μm silica gel or using a Biotage SP4 with GraceResolv™ silica cartridge.
Compounds 1-103 as provided below are previously described in WO2007/107758, WO2009/037485 WO2009/040507 and WO2012/142671 and may be prepared in accordance with the methods described therein.
Other compounds of Formula (I) and compounds of Formula (II) may be prepared according to the General Methods or Schemes previously described herein and/or by reference to the Representative Examples that follow.
Step 1: 2,6-difluoro-3-nitro-benzonitrile (3.1 g) was dissolved in sulfuric acid (3 mL) and heated to 90° C. for 20 minutes. The solution was poured onto ice and the precipitated white solid was collected by suction filtration. LCMS showed complete conversion to a product with a weak [M+NH4]+ ion (m/z=220). The filter cake was dissolved in THF (25 mL) and dried over MgSO4. The yellow solution of 2,6-difluoro-3-nitro-benzamide was then used in the next step without further purification.
Step 2: The THF solution of 2,6-difluoro-3-nitro-benzamide from Step 1 was treated with palladium on carbon (100 mg) and covered in an atmosphere of hydrogen at balloon pressure after evacuating the flask three times. The reaction mixture was stirred at room temperature for 70 h. The mixture was filtered to remove the charcoal then concentrated to dryness. The orange residue was recrystallised from isopropanol to yield the target 3-amino-2,6-difluorobenzamide as small tan crystals (1.2 g, 41%).
1H NMR (400 MHz, DMSO) δ 7.99 (s, 1H), 7.67 (s, 1H), 6.85-6.70 (m, 2H), 5.05 (br s, 2H).
Step 3: 1-Bromo-4-chloro-butane (1.5 mL, 13.5 mmol) and 4-(trifluoromethoxy)phenol (1.45 mL, 11.2 mmol) were dissolved in DMA (5 mL) and treated with potassium carbonate (2.3 g, 1.5 eq). The mixture was stirred at room temperature for 20 h. After this time the mixture was diluted with EtOAc (40 mL) and washed with water (3×40 mL). The organic phase was dried over MgSO4 and purified by silica chromatography (0%-30% gradient of EtOAc in heptane) to yield 1-(4-chlorobutoxy)-4-(trifluoromethoxy)benzene as a clear liquid (2.36 g, 78%).
Step 4: A solution of 3-amino-2,6-difluorobenzamide (0.70 g, 4.0 mmol) and 1-(4-chlorobutoxy)-4-(trifluoromethoxy)benzene (1.2 g, 1.2 eq) in DMA (1.0 mL) was treated with potassium carbonate (620 mg, 1.2 eq) and catalytic sodium iodide (50 mg, 0.33 mmol). The suspension was heated at 90° C. for 16 hours. After this time the mixture was diluted with EtOAc (100 mL) and washed with water (100 mL) and brine (3×60 mL). The organic layer was dried over MgSO4 and concentrated. The residue was purified by reverse-phase chromatography (5-100% gradient of MeCN/water) to yield the target 2,6-difluoro-3-[4-[4-(trifluoromethoxy)phenoxy]butylamino]benzamide (890 mg, 54%) as a light brown solid and the by-product 3-[bis[4-[4-(trifluoromethoxy)phenoxy]butyl]amino]-2,6-difluoro-benzamide (411 mg, 16%) as a yellow oil.
Step 5: A mixture of 2,6-difluoro-3-[4-[4-(trifluoromethoxy)phenoxy]butylamino]benzamide (100 mg, 0.247 mmol), K2CO3 (50 mg, 1.5 eq) and 2-bromoethanol (65 mg, 5 eq) in dry DMA (0.5 mL) was heated at 90° C. for 64 h. After this time the reaction was cooled and quenched by addition of water (1 mL). The mixture was diluted with EtOAc (2 mL). The organic phase was washed with water (2×1 mL), dried over MgSO4 and concentrated in vacuo. The residue was taken up in DMSO and purified by reverse phase MPLC (5-100% gradient of MeCN in water) to yield the target as a brown tacky gum (65 mg, 59%).
Prepared by analogous procedures were, for example, 3-[(3-cyanopropyl){4-[4-(trifluoromethoxy)phenoxy]butyl}amino]-2,6-difluorobenzamide and 2,6-difluoro-3-(methyl {4-[4-(trifluoromethoxy)phenoxy]butyl}amino)benzamide.
Step 1: A solution of 2,6-difluoro-3-hydroxy-benzamide (2.5 g, prepared as described in WO2012/142671) in DMA (10 mL) was treated with potassium carbonate (6 g, 3 eq) and 1-bromo-4-chloro-butane (1.66 mL, 1 eq) and stirred at 60° C. for 6 h.
Step 2: To the above suspension was added 4-(trifluoromethoxy)phenol (2.25 mL, 1.2 eq) and the mixture was stirred at 60° C. for 22 h, then 70° C. for 68 h. The mixture was quenched with water (100 mL) and washed with CH2Cl2 (3×100 mL). The combined organic layers were dried over MgSO4 and concentrated to dryness. The residue was purified by reverse-phase MPLC (50-100% gradient of MeOH in water). The product was freeze-dried from acetonitrile/water to obtain the title compound as a white fluffy solid (2.19 g, 37%).
Prepared by analogous procedures were, for example, 3-{[5-(4-chlorophenoxy)pentyl]oxy}-2,6-difluorobenzamide and 2,6-difluoro-3-(4-{[6-(trifluoromethyl)pyridazin-3-yl]oxy}butoxy)benzamide.
Similarly prepared was, for example, 2,6-difluoro-3-(2-{2-[4-(trifluoromethoxy)phenoxy]ethoxy}ethoxy)benzamide, using 2-(2-chloroethoxy)ethanol in place of 1-bromo-4-chloro-butane and then converting the free hydroxyl group to an alkyl chloride by means of thionyl chloride, then concentrating and resuspending in DMA prior to Step 2. Also similarly prepared were, for example, 3-{4-[(4-chlorophenyl)thio]butoxy}-2,6-difluorobenzamide, 2,6-difluoro-3-{4-[4-(pentafluoro-lambda-6-sulfanyl)phenoxy]butoxy}benzamide and 2,6-difluoro-3-(4-{[4-(trifluoromethoxy)phenyl]amino}butoxy)benzamide by using 4-chlorothiophenol, 4-pentafluorosulfanylphenol and 4-(trifluoromethoxy)aniline, respectively, in place of 4-(trifluoromethoxy)phenol.
Step 1: A sample of 2,6-difluoro-3-hydroxy-benzonitrile (300 mg) was dissolved in DMA (1 mL) and treated with potassium carbonate (400 mg, 1.5 eq) and 1-bromononane (442 μL, 1.2 eq). The mixture was stirred at 70° C. for 1 h. The mixture was diluted with water (20 mL) and washed with EtOAc (3×20 mL). The combined organic phases were dried over MgSO4 and concentrated to remove most of the volatiles. The colorless DMA solution thus obtained was used in the next step without further purification.
Step 2: The above solution of 2,6-difluoro-3-nonoxy-benzonitrile was dissolved in ethanol (5 mL) and treated with 50% w/v hydroxylamine in water (355 μL, 3 eq). The solution was stirred at 70° C. for 16 h. The mixture was cooled, diluted with water (25 mL) and washed with dichloromethane (3×40 mL). The combined organic phases were dried over MgSO4 and purified by silica chromatography (0-40% gradient of EtOAc in heptanes) to yield 2,6-difluoro-N′-hydroxy-3-(nonyloxy)benzenecarboximidamide as a white fluffy solid (366 mg, 60%) after freeze-drying from acetonitrile/water.
Step 3: Potassium formate solution was prepared by treating a solution of formic acid (377 μL, 10 mmol) in methanol (1 mL) with potassium carbonate (691 mg, 5 mmol) and sonicating until the evolution of gas had ceased.
A solution of 2,6-difluoro-N′-hydroxy-3-nonoxy-benzamidine (290 mg) in AcOH (1 mL) was treated with acetic anhydride (100 μL, 1.15 eq) at room temperature. After 30 minutes, the above potassium formate solution was added, followed by a catalytic amount of 10% Pd on carbon. The mixture was stirred at room temperature for 2 h, whereupon a second batch of the above potassium formate solution was prepared and added. The mixture was then stirred at room temperature overnight. The mixture was filtered and washed with ethanol. The filtrate was concentrated, resuspended in anhydrous methanol and then filtered again to remove the undissolved KCl. The filtrate was concentrated, resuspended in dichloromethane and filtered again to remove the undissolved crystals. The filtrate was purified by silica chromatography (0-70% gradient of MeOH in DCM containing 1% TEA) to yield the title compound as a white solid (158 mg, 57%).
Step 1: Magnesium turnings (420 mg) were added to a solution of 1-bromo-4-(trifluoromethyl)benzene (3.5 g, 16 mmol) in THF (20 mL) at room temperature. An iodine crystal was added and allowed to stand for 5 minutes. After this, stirring was commenced and the mixture began to heat at reflux under its own exotherm. After the exothermic reaction subsided, the mixture was stirred at reflux for a further 30 minutes before cooling to room temperature.
In a separate vessel, a green solution of copper(I) bromide (100 mg, 0.7 mmol) and lithium bromide (120 mg, 1.4 mmol) in THF (25 mL) was treated by rapid addition of 1,5-dibromopentane (9 g, 2.5 eq). The mixture was stirred at room temperature for 30 minutes then warmed to 40° C. The freshly prepared Grignard solution from above was then added over a period of approximately 2 minutes and the mixture was stirred at 55° C. for 3 h and subsequently at room temperature for 16 h. Saturated ammonium chloride solution (20 mL) and ice (20 mL) were added carefully to the reaction mixture. The mixture was washed three times with ethyl acetate and the combined organic phases were dried over MgSO4 and concentrated. The crude product was purified by silica chromatography (0-100% gradient of EtOAc in hexanes) to yield 1-bromo-4-(trifluoromethyl)benzene as a clear liquid that partially crystallised upon standing (500 mg).
Step 2: A solution of 2,6-difluoro-3-hydroxy-benzamide (100 mg) and 1-(5-bromopentyl)-4-(trifluoromethyl)benzene (300 mg) in DMA (0.7 mL) was treated with potassium carbonate (120 mg, 1.5 eq) and heated at 75° C. with stirring for 3.5 h.
The mixture was diluted with water (1 mL) and then washed with EtOAc (4×1 mL).
The combined organic layers were filtered through cotton wool, concentrated and purified by reverse-phase MPLC (5-100% gradient of MeCN in water). The product-containing fractions were freeze-dried to yield the title ether as a white solid (70 mg, 31%).
Step 1: A solution of 4-(trifluoromethoxy)aniline (2 g) in 5 M HCl (4 mL) and acetone (10 mL) was cooled in ice/acetone. To this, a solution of NaNO2 (860 mg, 1.1 eq) in water (1 mL) was slowly added at such a rate that the temperature stayed between −10 and 0° C. The resulting solution was stirred for 1 h before adding it to a cold mixture of NaOAc (2.8 g, 3 eq), ethanol (30 ml) and ethyl 2-chloroacetoacetate (1.86 g, 1 eq). After stirring the resulting mixture for 1 hour the precipitate was collected by filtration, washed with water and dried in vacuo to give ethyl (2Z)-2-chloro-2-[[4-(trifluoromethoxy)phenyl]hydrazono]acetate (2.87 g, 82%).
Step 2: A mixture of ethyl 1-[4-(trifluoromethoxy)phenyl]pyrazole-3-carboxylate (2.87 g), bicyclo[2.2.1]hepta-2,5-diene (5 mL, 5 eq) and triethylamine (3.8 mL, 3 eq) in toluene (20 mL) was stirred at 70° C. for 0.5 h. The mixture was cooled and filtered, the filter cake was washed with toluene and the filtrate was concentrated under vacuum. The residue was heated at reflux in xylenes (30 mL) for 1 h. The mixture was partially concentrated under vacuum then purified by silica chromatography (0-50% gradient of EtOAc in heptanes) to yield ethyl 1-[4-(trifluoromethoxy)phenyl]pyrazole-3-carboxylate as an orange oil (1.89 g, 68%).
Step 3: A solution of ethyl 1-[4-(trifluoromethoxy)phenyl]pyrazole-3-carboxylate (1.89 g) in THF (20 mL) was cooled in ice/water and cautiously treated with lithal (260 mg, 1.1 eq). The ice bath was withdrawn and the mixture was stirred at room temperature under nitrogen for 75 minutes. The mixture was cooled in ice/water and quenched with ice, then diluted with THF (30 mL) and a saturated solution of sodium potassium tartrate (Rochelle salt). The aqueous layer was washed again with THF (30 mL) and the combined organic extracts were dried over MgSO4 and concentrated to yield [1-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methanol as an orange oil, which crystallised on standing (1.53 g, 94% crude).
Step 4: A solution of crude [1-[4-(trifluoromethoxy)phenyl]pyrazol-3-yl]methanol (1.53 g) in dichloromethane (10 mL) was treated at room temperature with thionyl chloride (3 mL, 7 eq) and catalytic DMA (10 drops). The mixture initially boiled under its own exotherm. After 0.5 h the mixture was quenched with ice (20 mL). The aqueous layer was washed with dichloromethane (2×25 mL) and the combined organic layers were dried over MgSO4 and concentrated. The residue was purified by silica chromatography (0-50% gradient of EtOAc in heptanes) to yield 3-(chloromethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazole as an orange liquid (1.41 g, 86%).
Step 5: A mixture containing 2,6-difluoro-3-hydroxy-benzamide (150 mg), 3-(chloromethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazole (240 mg, 1.2 eq) and potassium carbonate (180 mg, 1.5 eq) in DMA (0.6 mL) was stirred at 90° C. for 19 h. The mixture was diluted with water (5 mL) and washed with a combination of dichloromethane, THF and EtOAc (20 mL). The combined organic extracts were partially concentrated under vacuum and the residue was purified by reverse-phase MPLC (5-100% gradient of MeCN in water) then freeze-dried to yield the title compound as a fluffy white solid (159 mg, 44%).
To a solution of (R)-3-(1-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-2-hydroxyethoxy)-2,6-difluorobenzamide (0.40 g, 0.79 mmol) in pyridine (10 mL) was added DMAP (catalytic) and succinic anhydride (0.08 g, 0.79 mmol). The resulting reaction mixture was allowed to stir at room temperature for 16 h. The reaction mixture was cooled to 0° C., adjusted to pH 4-5 by drop-wise addition of 6 M HCl and the product extracted into EtOAc (2×50 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (R)-4-(2-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-2-(3-carbamoyl-2,4-difluorophenoxy)ethoxy)-4-oxobutanoic acid (0.40 g, 84%).
To a solution of (R)-4-(2-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-2-(3-carbamoyl-2,4-difluorophenoxy)ethoxy)-4-oxobutanoic acid (0.30 g, 0.49 mmol) in methanol:DCM (1:1, 8 mL) was added L-arginine (0.086 g, 0.49 mmol). The resulting reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (TLC monitoring) the mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether to afford (R)-4-(2-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-2-(3-carbamoyl-2,4-difluorophenoxy)ethoxy)-4-oxobutanoic acid L-arginine salt as an off white solid (0.30 g, 78%).
Similarly prepared was 4-(2-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-2-(3-carbamoyl-2,4-difluorophenoxy)ethoxy)-4-oxobutanoic acid L-arginine salt.
An ethanolic solution of methylamine (1.26 mmol) and formaldehyde (1.26 mmol) was stirred for 15 min at room temperature followed by addition of 3-[(6-chlorothiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluoro-benzamide (0.10 g, 0.21 mmol). The resulting reaction mixture was stirred at 80° C. for 16 h. The reaction mass was then concentrated under reduced pressure and finally triturated with n-pentane to obtain the title product.
Compounds 104-121 of Formula (I) were characterised using a combination of LCMS and 1H NMR data provided in Table 1 and 1a.
1H NMR
1H NMR (400 MHz, DMSO) δ 8.15 (br
1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 2.5 Hz,
1H NMR (400 MHz, DMSO) δ 8.43 (d,
1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.0 Hz,
1H NMR (400 MHz, CDCl3) δ 7.87 (d , J = 8.9 Hz,
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 9.0 Hz,
1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.9 Hz,
1H NMR (400 MHz, DMSO-d6) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Acetone) δ 8.18 (s,
Compounds 122-123 of Formula (Ia) were characterised using a combination of LCMS and 1H NMR data provided in Table 2.
1H NMR
2,6-difluoro-3-[({4-[4- (trifluoromethyl)phenyl]-1,3-thiazol-2- yl}methyl)amino]benzamide
1H NMR (400 MHz, DMSO- d6) δ 8.23 (s, 1H), 8.17 (d, J = 8.1 Hz, 2H), 8.08 (br s, 1H), 7.81 (d, J = 8.3 Hz, 2H), 7.75 (br s, 1H), 6.88 (t, J = 8.9 Hz, 1H), 6.60 (dt, J = 5.8, 2.9 Hz, 1H), 4.70 (d, J = 6.1 Hz, 2H).
2,6-difluoro-3-(nonylamino)benzamide
1H NMR (400 MHz, DMSO) δ 8.00 (s, 1H), 7.69 (s, 1H), 6.87 (td, J = 8.9, 1.5 Hz, 1H), 6.66 (td, J = 9.4, 5.5 Hz, 1H), 5.32 (td, J = 5.7, 1.9 Hz, 1H), 3.03 (dd, J = 13.6, 6.5 Hz, 2H), 1.60-1.44 (m, 2H), 1.35-1.19 (m, 12H), 0.86 (t, J = 6.9 Hz, 3H).
Compounds 124-187 of Formula (II) were characterised using a combination of LCMS and 1H NMR data provided in Table 3.
1H NMR
1H NMR (400 MHz, DMSO) δ 8.11 (br
1H NMR (400 MHz, DMSO) δ 8.10 (s,
1H NMR (400 MHz, Acetone) δ 7.44 (d,
1H NMR (400 MHz, Acetone) δ 7.96 (d,
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 8.1 Hz,
1H NMR (400 MHz, DMSO-d6) δ
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ 8.12 (d,
1H NMR (400 MHz, DMSO) δ 8.44 (d, J = 2.8 Hz,
1H NMR (400 MHz, Acetone) δ 7.42 (br
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, DMSO) δ 8.09 (s,
1H NMR (400 MHz, DMSO) δ 8.09 (s,
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, DMSO-d6) δ
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.0 Hz,
1H NMR (400 MHz, DMSO) δ
1H NMR (400 MHz, DMSO) δ 8.13 (d, J = 9.3 Hz,
1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 9.3 Hz,
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ
1H NMR (400 MHz, Acetone) δ
1H NMR (400 MHz, Acetone) δ 7.51 (t, J = 7.9 Hz,
1H NMR (400 MHz, Acetone) δ
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ 7.56 (d,
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, DMSO) δ 8.09 (br
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ
1H NMR (400 MHz, Acetone) δ 7.53 (t, J = 8.2 Hz,
1H NMR (400 MHz, Acetone) δ 7.39 (br
1H NMR (400 MHz, Acetone) δ 8.09 (br
1H NMR (400 MHz, Acetone) δ 7.69 (d,
1H NMR (400 MHz, DMSO-d6) δ
1H NMR (400 MHz, DMSO-d6) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Acetone-d6) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Chloroform-d) δ
1H NMR (400 MHz, Acetone-d6) δ
Additionally prepared, in accordance with methods known in the art or by reference to the methods described herein, were further compounds of Formula (I) 188-213 as provided below.
The chiral HPLC conditions used to separate Compound 32 are as follows:
Preparative Method:
Column: CHIRALPAK® AD-H, (250×30) mm, 5 μm
Mobile phase: n-Hexane:EtOH:MeOH (80:10:10 v/v/v)
Flow rate: 40 ml/min
Detection: UV 265 nm
Temperature: 25° C.
Diluent: Mobile phase
Feed Conc.: 9.0 mg/ml
Inj Volume: 7 ml (on column: 63 mg)
Analytical Method:
Column: CHIRALPAK® IA (250×4.6) mm, 5 m
Mobile phase: n-Hexane:EtOH (80:20 v/v)
Flow rate: 1.0 ml/min
Detection: DAD 265 nm
Temperature: 25° C.
Isomer-A: 9.20 min (Isomeric purity 99.30%)
Isomer-B (Compound 47): 9.90 min (Isomeric purity 99.60%) was determined to be the
(R)-enantiomer with absolute configuration as follows:
The in vitro antiviral activity of the compounds of the invention may be determined using the following protocols.
Bacterial Assay: Determination of Antibacterial Activity Compounds of the invention were tested for antimicrobial activity by susceptibility testing in liquid or on solid media. Minimum inhibitory concentrations (MICs) for compounds against each strain were determined by the broth microdilution or agar dilution method according to the guidelines of the Clinical Laboratories and Standards Institute, formerly the National Committee for Clinical Laboratory Standards (Clinical Laboratories and Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Anaerobically; Approved Standard-Seventh Edition. Document M11-A7, CLSI, Wayne, Pa., 2007, Clinical Laboratories and Standards Institute). Briefly MICs were determined by visible inspection after 48 hours of growth in the presence of compounds, cultures were grown at 37° C. in anaerobic gas packs using reinforced clostridial medium supplemented with 0.1% defribrinated horse blood. The bacterial strains tested include C. difficile (Clostridium difficile (Isolate ID ATCC 9689)) (Table 2) and two drug resistant clinical isolates (Clostridium difficile (Isolate ID BI-9) and Clostridium difficile (Isolate ID 027-01) (Table 3).
MICs were determined to be within the activity ranges “A” activity≦1.01 μg/mL; “B” activity>1.0 μg/mL-4.0 μg/mL; “C” activity>4.0 μg/mL-16 μg/mL
C. difficile
C. difficile
C. difficile
C. difficile (B-I9)
C. difficile (027-01)
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference in this specification to any prior publication, or information derived from it, or to any matter which is known, is not, and should not be taken as an acknowledgement or admission or any form of suggestion that that prior publication, or information derived from it, or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2014901885 | May 2014 | AU | national |
| 2014901912 | May 2014 | AU | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2015/032052 | 5/21/2015 | WO | 00 |
